venBio Partners — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesVida Ventures+1 more
NFlection is a biopharmaceutical company developing novel therapeutics.
BiotechMedical DevicesBoston, US
Christopher Powala(Chief Development Officer, Former President & CEO)Mark de Souza(Executive Officer, Director)in
BoardCorey Goodman(Director)Ketan Patel(Director)in
Co-investorsF-Prime CapitalvenBio Global Strategic
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Abdera Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.